BRCA1 and ovarian carcinoma: Poly(ADP-ribose) polymerase inhibitors (PARPi) are effective in treating cancers with mutations in the hereditary breast and ovarian cancer genes, BRCA1 or BRCA2 (BRCA)1,2.